MR molecular imaging of prostate cancer with a small molecular CLT1 peptide targeted contrast agent.

Abstract

Tumor extracellular matrix has abundance of cancer related proteins that can be used as biomarkers for cancer molecular imaging. In this work, we demonstrated effective MR cancer molecular imaging with a small molecular peptide targeted Gd-DOTA monoamide complex as a targeted MRI contrast agent specific to clotted plasma proteins in tumor stroma. We performed the experiment of evaluating the effectiveness of the agent for non-invasive detection of prostate tumor with MRI in a mouse orthotopic PC-3 prostate cancer model. The targeted contrast agent was effective to produce significant tumor contrast enhancement at a low dose of 0.03 mmol Gd/kg. The peptide targeted MRI contrast agent is promising for MR molecular imaging of prostate tumor.

• Authors: Xueming Wu, Daniel Lindner, Guan-Ping Yu, Susann Brady-Kalnay, Zheng-Rong Lu
• Journal: Journal of visualized experiments : JoVE (J Vis Exp) Issue 79 (Sep 03 2013) ISSN: 1940-087X [Electronic] United States
• PMID: 24056726 (Publication Type: Journal Article, Research Support, N.I.H., Extramural, Research Support, Non-U.S. Gov't, Video-Audio Media)

Chemical References

• Contrast Media
• Heterocyclic Compounds
• Organometallic Compounds
• Peptides, Cyclic
• cyclo(cysteinyl-glycyl-leucyl-isoleucyl-isoleucyl-glutaminyl-lysyl-asparaginyl-glutamyl-cysteinyl)
• gadolinium 1,4,7,10-tetraazacyclododecane-N,N',N'',N'''-tetraacetate

Topics

• Animals
• Contrast Media (chemical synthesis, chemistry, pharmacokinetics)
• Heterocyclic Compounds (chemistry, pharmacokinetics)
• Humans
• Magnetic Resonance Imaging (methods)
• Male
• Mice
• Mice, Nude
• Molecular Imaging (methods)
• Organometallic Compounds (chemistry, pharmacokinetics)
• Peptides, Cyclic (chemical synthesis, chemistry, pharmacokinetics)
• Prostatic Neoplasms (chemistry, metabolism, pathology)